Xilio Therapeutics
Xilio Therapeutics, based in Waltham, Massachusetts, specializes in developing tumor-activated immunotherapies aimed at treating cancer with minimal systemic side effects.
Immunotherapy Services
Xilio Therapeutics focuses on developing tumor-activated immunotherapies aimed at cancer treatment. By utilizing its proprietary GPS Platform, the company is dedicated to minimizing systemic side effects while effectively targeting tumor microenvironments. Their services revolve around advancing clinical trials for investigational drugs, ensuring the efficacy and safety of their therapeutic solutions.
Headquarters
Xilio Therapeutics is headquartered in Waltham, Massachusetts. This location serves as the central hub for its research and development activities, enabling the company to leverage both the intellectual and industrial resources in the region to advance their cancer treatment therapies.
Therapeutic Pipeline
The therapeutic pipeline of Xilio Therapeutics includes several key investigational drugs: XTX101 (an anti-CTLA-4 therapy), XTX202 (an IL-2 based therapy), and XTX301 (an IL-12 based therapy). These drugs are designed to be tumor-activated, which helps in minimizing systemic side effects while targeting the tumor microenvironment effectively. The company is actively engaged in clinical trials to assess the safety and efficacy of these drugs.
Clinical Trials
Xilio Therapeutics conducts clinical trials to evaluate its investigational drugs. These trials are critical in determining the therapeutic potential and safety of their tumor-activated immunotherapies. Currently, the company does not offer an expanded access program for these investigational drugs.
Investments and Partnerships
On March 28, 2024, Xilio Therapeutics announced a $11.3 million private placement equity financing to support its ongoing research and development activities. Additionally, the company entered into an exclusive license agreement with Gilead for its tumor-activated IL-12 program. These strategic moves are crucial for advancing their therapeutic pipeline and scaling their operational capabilities.